NCT01361529 is a Phase 1 clinical trial of FLP,dose escalation,MTD in Advanced Cancer, sponsored by Acea Bio (Hangzhou) Co., Ltd..

Who is sponsoring NCT01361529?

NCT01361529 is sponsored by Acea Bio (Hangzhou) Co., Ltd..

What drugs are being tested in NCT01361529?

Interventions in NCT01361529: FLP,dose escalation,MTD.

What condition does NCT01361529 study?

NCT01361529 studies Advanced Cancer.

Is NCT01361529 still recruiting?

NCT01361529 is currently status unknown. Last updated 26 May 2011.

Last reviewed 2011-05-26 · How we verify

NCT01361529

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Study of FLP Injection on Tumor Patients

Status unknown Phase 1 Last updated 26 May 2011

What this trial tests

Phase 1 trial testing FLP,dose escalation,MTD in Advanced Cancer in 30 participants. Status unknown.

Timeline

1 June 2009

Primary endpoint
1 June 2011

1 July 2011

Quick facts

Lead sponsor	Acea Bio (Hangzhou) Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 June 2009
Primary completion	1 June 2011
Estimated completion	1 July 2011
Sites	1 location across China

Drugs / interventions tested

FLP,dose escalation,MTD — full drug profile →

Conditions studied

Advanced Cancer — all drugs for Advanced Cancer →

Sponsor

Acea Bio (Hangzhou) Co., Ltd. — full company profile →

Who can join

Adults 18 to 70, any sex, with Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

adverse effect assessment
Time frame: 21 days
to evlauate the symptom of adverse effect and the number of participates with adverse effect

Sponsor's own description

The purpose of this study is to determine the tolerance and maximum tolerated dose (MTD) for FLP Injection with multiple dose in tumor patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01361529 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Acea Bio (Hangzhou) Co., Ltd.
Last refreshed: 26 May 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01361529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing